Raloxifene in Hemodialysis Patients

authors:

avatar Frieder Keller 1 , *

Nephrology Department, University Hospital, Ulm, Germany
International Journal of Endocrinology and Metabolism: Vol.10, issue 3; 576-576
published online: June 30, 2012
article type: Letter
received: May 6, 2012
revised: May 7, 2012
accepted: May 7, 2012
DOI: https://doi.org/10.5812/ijem.5457

how to cite: Keller F. Raloxifene in Hemodialysis Patients. Int J Endocrinol Metab. 2012;10(3): 576-576. https://doi.org/10.5812/ijem.5457.

References

  • 1.

    Saito O, Saito T, Asakura S, Akimoto T, Inoue M, Ando S, et al. Effects of raloxifene on bone metabolism in hemodialysis patients with type 2 diabetes. Int J Endocrinol Metab. 2012;10:464-9. https://doi.org/10.5812/ijem.3794.

  • 2.

    Czock D, Keller F, Heringa M, Rasche FM. Raloxifene pharmacokinetics in males with normal and impaired renal function. Br J Clin Pharmacol. 2005;59(4):479-82. [PubMed ID: 15801944]. https://doi.org/10.1111/j.1365-2125.2004.02326.x.

  • 3.

    Ishani A, Blackwell T, Jamal SA, Cummings SR, Ensrud KE. The effect of raloxifene treatment in postmenopausal women with CKD. J Am Soc Nephrol. 2008;19(7):1430-8. [PubMed ID: 18400939]. https://doi.org/10.1681/ASN.2007050555.